Geron Corporation (NASDAQ:GERN) : During the past 4 weeks, traders have been relatively bearish on Geron Corporation (NASDAQ:GERN), hence the stock is down -3.36% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.34% relative to the S&P 500. The 4-week change in the price of the stock is -1.81% and the stock has fallen -1.09% in the past 1 week.
The company shares have dropped -37.04% from its 1 Year high price. On Dec 2, 2015, the shares registered one year high at $5.30 and the one year low was seen on Feb 26, 2016. The 50-Day Moving Average price is $2.78 and the 200 Day Moving Average price is recorded at $3.04.
The stock has recorded a 20-day Moving Average of 1.19% and the 50-Day Moving Average is 2.56%.
Geron Corporation (NASDAQ:GERN): stock turned positive on Friday. Though the stock opened at $2.7, the bulls momentum made the stock top out at $2.75 level for the day. The stock recorded a low of $2.68 and closed the trading day at $2.72, in the green by 1.12%. The total traded volume for the day was 1,478,662. The stock had closed at $2.69 in the previous days trading.
In an insider trading activity, Bloom Olivia Kyusuk, officer (EVP, Chief Financial Officer) of Geron Corp, unloaded 2,380 shares at an average price of $3.84 on May 29, 2015. The total amount of the transaction was worth $9,139, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.